share_log

RBC Capital Reiterates Outperform on Allogene Therapeutics, Maintains $10 Price Target

Moomoo 24/7 ·  Mar 15 12:19

RBC Capital analyst Luca Issi reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and maintains $10 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment